211 related articles for article (PubMed ID: 18562053)
21. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
Chen X; Rock MT; Hammonds J; Tartaglia J; Shintani A; Currier J; Slike B; Crowe JE; Marovich M; Spearman P
J Virol; 2005 May; 79(9):5537-47. PubMed ID: 15827168
[TBL] [Abstract][Full Text] [Related]
22. A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
Eller MA; Slike BM; Cox JH; Lesho E; Wang Z; Currier JR; Darden JM; Polonis VR; Vahey MT; Peel S; Robb ML; Michael NL; Marovich MA
PLoS One; 2011; 6(9):e24254. PubMed ID: 21949699
[TBL] [Abstract][Full Text] [Related]
23. Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice.
Norton TD; Zhen A; Tada T; Kim J; Kitchen S; Landau NR
Mol Ther; 2019 May; 27(5):960-973. PubMed ID: 30962161
[TBL] [Abstract][Full Text] [Related]
24. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
Clements-Mann ML; Weinhold K; Matthews TJ; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Hsieh RH; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright PF; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker MC; Stablein D; Excler JL; Tartaglia J; Paoletti E
J Infect Dis; 1998 May; 177(5):1230-46. PubMed ID: 9593008
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
[TBL] [Abstract][Full Text] [Related]
26. Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction.
Donhauser N; Pritschet K; Helm M; Harrer T; Schuster P; Ries M; Bischof G; Vollmer J; Smola S; Schmidt B;
PLoS One; 2012; 7(3):e33925. PubMed ID: 22470494
[TBL] [Abstract][Full Text] [Related]
27. CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells.
Franco D; Liu W; Gardiner DF; Hahn BH; Ho DD
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):393-400. PubMed ID: 21239998
[TBL] [Abstract][Full Text] [Related]
28. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.
Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J
Tumori; 2015; 101(6):637-43. PubMed ID: 25983089
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).
Tubiana R; Carcelain G; Vray M; Gourlain K; Dalban C; Chermak A; Rabian C; Vittecoq D; Simon A; Bouvet E; El Habib R; Costagliola D; Calvez V; Autran B; Katlama C;
Vaccine; 2005 Jul; 23(34):4292-301. PubMed ID: 15927325
[TBL] [Abstract][Full Text] [Related]
30. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
31. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
Sin JI; Kim JJ; Zhang D; Weiner DB
Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230
[TBL] [Abstract][Full Text] [Related]
32. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.
Ferrari G; Humphrey W; McElrath MJ; Excler JL; Duliege AM; Clements ML; Corey LC; Bolognesi DP; Weinhold KJ
Proc Natl Acad Sci U S A; 1997 Feb; 94(4):1396-401. PubMed ID: 9037064
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.
Papagno L; Alter G; Assoumou L; Murphy RL; Garcia F; Clotet B; Larsen M; Braibant M; Marcelin AG; Costagliola D; Altfeld M; Katlama C; Autran B;
AIDS; 2011 Jan; 25(1):27-36. PubMed ID: 21076273
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
[TBL] [Abstract][Full Text] [Related]
35. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.
Ferrari G; Neal W; Ottinger J; Jones AM; Edwards BH; Goepfert P; Betts MR; Koup RA; Buchbinder S; McElrath MJ; Tartaglia J; Weinhold KJ
J Immunol; 2004 Aug; 173(3):2126-33. PubMed ID: 15265949
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
37. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition.
Yu Q; Yue FY; Gu XX; Schwartz H; Kovacs CM; Ostrowski MA
J Immunol; 2006 Feb; 176(4):2486-95. PubMed ID: 16456009
[TBL] [Abstract][Full Text] [Related]
38. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
39. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
Gorse GJ; Patel GB; Belshe RB;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1175-89. PubMed ID: 11522187
[TBL] [Abstract][Full Text] [Related]
40. An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection.
Kornbluth RS
J Hematother Stem Cell Res; 2002 Oct; 11(5):787-801. PubMed ID: 12427285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
